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Cellular and genetic tumor heterogeneity
The era of personalized medicine has been launched,
with all its promises and hopes. Take cancer, for
instance, where deep sequencing will make it possible to
assess virtually all genomic alterations in a patient’s
tumor tissue, and this at affordable costs. Already now,
genomic testing can be used to predict whether or not a
breast or colon cancer patient might benefit from a
given treatment or whether the tumor of a melanoma
patient carries a pathway mutation making it susceptible
to specific pharmacological inhibitors. However, certain
tumors such as melanoma are characterized by an abun-
dance of mutations, and it is very demanding to deter-
mine which of these mutations are driver (providing a
selective advantage to a tumor cell) or passenger (having
no biological implication) mutations [1,2]. In many can-
cers, an astonishing inter- as well as intra-tumor hetero-
geneity makes it even more challenging to define
prognostic signatures and potential therapies. Not only
is the tumor of one patient different from the tumor of
another patient, but also primary and metastatic lesions
from different sites in the same patient exhibit vast gen-
omic variations [3]. Even within a given biopsy there is
cellular and genetic heterogeneity, which is likely associ-
ated with cellular differences in proliferation, survival
mechanisms, invasiveness, and drug resistance [4]. This
might explain why in melanoma, for instance, current
targeted treatments only marginally improve perspec-
tives for patients.
Formation of tumor heterogeneity: learning from
developmental biology
How heterogeneity is established within a tumor is of
relevance, because knowledge of this process might in-
form about alternative treatment strategies. One model
involves cancer stem cells that - like normal stem cells -
are able to self-renew (thus contributing to tumor
propagation) and to generate cellular heterogeneity by
multi-lineage differentiation. Alternatively, tumor het-
erogeneity might arise by clonal evolution, driven by
mutations that confer growth advantage of a cell and its
clonal progeny over other cells. Possibly, these models
are not mutually exclusive: for instance, a driver muta-
tion might have to occur in a cell with stem cell proper-
ties in order for it to elicit its driving force. Or a
mutation might promote cancer ‘stemness’ by repro-
gramming a cell that lacked this potential before. In any
case, cellular heterogeneity existing prior to treatment
could lead to resistance, in that intrinsic differences be-
tween different tumor cell fractions may influence drug
responsiveness and promote selective growth, for ex-
ample, of cancer stem cells or of cells with a distinct
mutation signature. Thus, it is important to identify in-
trinsic properties characteristic for the various tumor
cell fractions and, optimally, to find features common to
all cell lineages making up a tumor.
Intrinsic properties of a tumor cell are conceivably de-
termined by the cell’s developmental origin and cell
lineage relationships. Indeed, tumors often share cellular
and molecular features with cells of the tissue from
which the tumor derived. In particular, there is increas-
ing evidence that the developmental program of the
tissue of origin is replayed during tumorigenesis. Melan-
oma, as an example, results from transformation of cells
of the melanocyte lineage, which during embryonic
development arises from neural crest cells. Intriguingly,
it has recently been demonstrated that mechanisms
underlying embryonic neural crest cell and melanocyte
development also control melanoma formation in vivo
[5]. In this study, the neural crest stem cell factor
SOX10 was shown to be highly up-regulated in both
murine and human melanoma cells; decreasing its
expression levels prevented tumorigenesis without
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affecting normal melanocyte stem cell function. Like-
wise, the small Rho GTPase Rac1 is a factor known to
be required for self-renewal and expansion of postmigra-
tory neural crest stem cells [6], and recently, an activat-
ing mutation in RAC1 has been identified to drive
melanoma formation [7]. Thus we might be guided by
developmental biology for the detection of novel players
in tumor biology and hence to potential tumor therapy
targets.
Influences of environmental factors on intra-
tumor heterogeneity
In addition to genetics, epigenetic mechanisms are crucial
players in tumorigenesis. Because of their reversibility, epi-
genetic modifications likely allow dynamic switching from
a silent state to growth and invasiveness, respectively, and
could thus also contribute to intra-tumor heterogeneity
or differences between primary tumors and their metasta-
ses. Such epigenetic modifications may be imposed on a
tumor cell by microenvironmental pressure, such as
provided by changes in oxygen levels, metabolites, or in-
teractions with non-tumor cells. In addition, dynamic
epigenetic changes are possibly a consequence of pharma-
cological drug exposure, which could be associated with
resistance acquired during treatment. For instance,
pharmacological inhibition of a given pathway might be
circumvented in a cell by epigenetic de-repression of a
novel compensatory pathway. In melanoma, dynamic
changes of cell behavior have been observed in cell culture
and in vivo upon exposure to inflammatory factors such
as tumor necrosis factor-α [8]. Whether these changes in-
deed involve epigenetic reprogramming rather than selec-
tion of specific cell fractions is an open question that
remains to be addressed, ultimately by single cell tracing
in an in vivo context.
All in all, the various mechanisms possibly leading to
intra-tumor heterogeneity ask for combinatorial treat-
ment strategies. These may consist in targeting specific
pathways together with inhibition of more general pro-
cesses, such as those involving epigenetic control mech-
anisms. Ultimately, the clinics will tell [9] whether this
approach will be successful in eradicating all tumori-
genic cells in a patient - or at least in keeping them in
check.
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